Patterns in opioid prescription in the United States by region and prescribers over a 4-year period

Luisa M. Bigal, BA; Kristen Bibeau, PhD; Stephanie Dumbar, PhD

doi:10.5055/jom.2019.0541

Authors

Luisa M. Bigal, BA
Kristen Bibeau, PhD
Stephanie Dumbar, PhD

DOI:

https://doi.org/10.5055/jom.2019.0541

Keywords:

opioid, prevalence, patterns of prescription

Abstract

Background: As determinants of the opioid epidemic are several, describing patterns of opioid prescription over time is of importance.

Objective: To characterize the prescribing patterns of opioids per US region and physician specialty from 2012 to 2015.

Methods: Truven Health Analytics MarketScan® Databases were used to obtain data on opioid prescription rates per US region and physician specialty for the years 2012-2015. Opioids included in the study are tramadol, hydrocodone, codeine, oxycodone, oxymorphone, methadone, and fentanyl.

Results: Starting sample consisted of 5,860,096 individuals. An increase in prescriptions was seen for codeine (22.3 percent), oxycodone (22.4 percent), and tramadol (22.4 percent), while other opioids had decreases between 6.5 and 20.2 percent during this period. Family medicine physicians were the most frequent prescriber for all opioids except for oxycodone; nonphysician prescribers’ share of prescriptions nearly doubled for all opioids. The share of oxycodone and of tramadol among all opioids increased in all regions, while the opposite was seen for hydrocodone. Codeine prescription share increased substantially in the South but not in other regions. When comparing the period of 2012-2015, differences were significant for all regions (p < 0.0001 for all regions). In 2015, the rate of prescription of oxycodone was nearly twofold higher in the Northeast vs North Central (38 percent vs 18.5 percent, p < 0.0001), while tramadol was substantially more frequently prescribed in the South, where it responded to nearly 20 percent of all opioid prescriptions (p < 0.0001).

Conclusion: Patterns of prescription per opioid vary considerably per physician specialty and per US region. Although an overall decrease in prescriptions was seen, certain opioids were more frequently prescribed in 2015 than in 2012.

Author Biographies

Luisa M. Bigal, BA

Undergraduate in Global Health and International Comparative Government, Duke University, Durham, North Carolina

Kristen Bibeau, PhD

Head, Global Health Outcomes and Real World Evidence Generation, Incyte Pharma, Chadds Ford, Pennsylvania

Stephanie Dumbar, PhD

Head of Clinical Operations, Biometrics and Data Sciences, Teva Pharmaceuticals, Horsham, Pennsylvania

References

Dowell D, Haegerich TM, Chou R: CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. 2016; 315(15): 1624-1645.

Kahan M, Mailis-Gagnon A, Tunks E: Canadian guideline for safe and effective use of opioids for chronic non-cancer pain: Implications for pain physicians. Pain Res Manag. 2011; 16(3): 157-158.

Pouget ER, Fong C, Rosenblum A: Racial/ethnic differences in prevalence trends for heroin use and non-medical use of prescription opioids among entrants to opioid treatment programs, 2005-2016. Subst Use Misuse. 2018; 53(2): 290-300.

Daubresse M, Chang HY, Yu Y, et al.: Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000- 2010. Med Care. 2013; 51(10): 870-878.

Musich S, Wang SS, Slindee L, et al.: Prevalence and characteristics associated with high dose opioid users among older adults. Geriatr Nurs. 2019; 40(1): 31-36.

Moran RA, Klapheke R, John GK, et al.: Prevalence and predictors of pain and opioid analgesic use following total pancreatectomy with islet autotransplantation for pancreatitis. Pancreatology. 2017; 17(5): 732-737.

US Department of Health and Human Services, SAMHSA, Center for Behavioral Health Statistics and Quality: Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2012. NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. Available at https://www.samhsa.gov/data/sites/default/files/NSDUHresults2012/NSDUHresults2012.pdf. Accessed August 9, 2018.

Hedegaard HWM, Miniño AM: Drug overdose deaths in the United States, 1999–2016. 2017. Available at https://www.cdc.gov/nchs/products/databriefs/db294.htm. Accessed August 9, 2018.

Reinhart M, Scarpati LM, Kirson NY, et al.: The economic burden of abuse of prescription opioids: A systematic literature review from 2012 to 2017. Appl Health Econ Health Policy. 2018; 16(5): 609-632.

Dasgupta N, Beletsky L, Ciccarone D: Opioid crisis: No easy fix to its social and economic determinants. Am J Public Health. 2018; 108(2): 182-186.

Pezalla EJ, Rosen D, Erensen JG, et al.: Secular trends in opioid prescribing in the USA. J Pain Res. 2017; 10: 383-387.

Volkow ND, McLellan AT: Opioid abuse in chronic pain—Misconceptions and mitigation strategies. N Engl J Med. 2016; 374(13): 1253-1263.

Truven Health Analytics: Market scan studies: Abbreviated bibliography. 2018. Available at http://truvenhealth.com/Portals/0/Assets/2017_Truven_Health_MarketScan_Bibliography.pdf. Accessed September 14, 2018.

DeGrauw X, Thurman D, Xu L, et al.: Epidemiology of traumatic brain injury-associated epilepsy and early use of anti-epilepsy drugs: An analysis of insurance claims data, 2004-2014. Epilepsy Res. 2018; 146: 41-49.

Young JC, Lund JL, Dasgupta N, et al.: Opioid tolerance and clinically recognized opioid poisoning among patients prescribed extended-release long-acting opioids. Pharmacoepidemiol Drug Saf. 2019; 28(1): 39-47.

Puenpatom RA, Szeinbach SL, Ma L, et al.: Daily average consumption of 2 long-acting opioids: An interrupted time series analysis. Am Health Drug Benefits. 2012; 5(1): 52-60.

US Food and Drug Administration: FDA Drug Safety Communication: FDA recommends against the continued use of propoxyphene. 2010. Available at https://www.fda.gov/Drugs/DrugSafety/ucm234338.htm. Accessed August 7, 2018.

Levy B, Paulozzi L, Mack KA, et al.: Trends in opioid analgesic- prescribing rates by specialty, U.S., 2007-2012. Am J Prev Med. 2015; 49(3): 409-413.

O’Donnell JK, Gladden RM, Seth P: Trends in deaths involving heroin and synthetic opioids excluding methadone, and law enforcement drug product reports, by census region—United States, 2006-2015. MMWR Morb Mortal Wkly Rep. 2017; 66(34): 897-903.

Vadivelu N, Kai AM, Kodumudi V, et al.: The opioid crisis: A comprehensive overview. Curr Pain Headache Rep. 2018; 22(3): 16.

Liang Y, Turner BJ: National cohort study of opioid analgesic dose and risk of future hospitalization. J Hosp Med. 2015; 10(7): 425-431.

Hsu DJ, McCarthy EP, Stevens JP, et al.: Hospitalizations, costs and outcomes associated with heroin and prescription opioid overdoses in the United States 2001-12. Addiction. 2017; 112(9): 1558-1564.

Minegishi T, Garrido MM, Pizer SD, et al.: Effectiveness of policy and risk targeting for opioid-related risk mitigation: A randomised programme evaluation with stepped-wedge design. BMJ Open. 2018; 8(6): e020097.

Beaudoin FL, Janicki A, Zhai W, et al.: Trends in opioid prescribing before and after implementation of an emergency department opioid prescribing policy. Am J Emerg Med. 2018; 36(2): 329-331.

Morin KA, Eibl JK, Franklyn AM, et al.: The opioid crisis: Past, present and future policy climate in Ontario, Canada. Subst Abuse Treat Prev Policy. 2017; 12(1): 45.

Minnesota Department of Health: Patterns of opioid prescribing in Minnesota: 2012 and 2015. 2018. Available at https://www.health.state.mn.us/data/economics/docs/opioidbrief20185.pdf. Accessed August 17, 2018.

Toth AR, Possidente CJ, Sawyer LM, et al.: National and Northern New England opioid prescribing patterns, 2013-2014. Pain Med. 2017; 18(9): 1706-1714.

McDonald DC, Carlson K, Izrael D: Geographic variation in opioid prescribing in the U.S. J Pain. 2012; 13(10): 988-996.

Jeffrey Kao MC, Minh LC, Huang GY, et al.: Trends in ambulatory physician opioid prescription in the United States, 1997- 2009. PM R. 2014; 6(7): 575-582.e4.